Press Room

Oral and Inhalation Solid Dosage Forms Workshop

Start
Wednesday, March 27, 2019 - 00:00
End
Wednesday, March 27, 2019 - 00:00
Location: Switzerland
Oral Inhalation nasal Solid Dosage Forms | Hovione

 

Hovione is present at the Oral and Inhalation Solid Dosage Forms Workshop with a presentation by Maria Braga, Scientist of R&D Drug Product Development.

The workshop, organised at the MG2 premises on March Wednesday 27th, gives delegates the possibility to meet different industrial partners in a real market place; a place in which Academy and Industry can share their experiences and knowledge.

This event will last one day, divided in 2 different moments: speeches in the morning and workshop in the afternoon at MG2 Factory.

 

HOVIONE PRESENTATION

Title: From the engineered particle to lung deposition: how to successfully develop a carrier-based DPI?

Time: 9:30 am

Presenter: Maria Braga, Scientist of R&D Drug Product Development

 

 

If you would like to find more about Hovione's full range of inhalation drug development servicesparticle engineering and development by design schedule a meeting with us

Schedule a meeting button | Hovione

 

 

 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024